The New Liver Lexicon
NASH by any other name would still be fatty liver (but going forward call it SLD)
Leveraging eC-SSRS for Suicide Risk Assessment
Discover how eC-SSRS is redefining suicide risk assessments with unprecedented accuracy and reliability in oncology trials and beyond
Knowledge is Power: 5 Important Questions You Should Ask Your Sales Rep
How to ensure your prospective provider meets the gold standard for operations and data collection in medical imaging, cardiac safety, and eCOA
Ensuring Patient-Centered Care in Oncology Trials
From centralized ECGs to patient-reported outcomes – a guide to optimizing assessments of drug safety and quality of life
Designing a successful imaging-based pediatric oncology trial
Navigating complexities for improved clinical outcomes
The Heart of the Matter
Sudden Cardiac Arrest in Young Athletes and Those Working to Prevent It
Embracing Accessibility: The Future of Clinical Trials
Harnessing Accessibility Functionalities to Broaden Patient Participation and Ensure Data Integrity
Frequently Asked Questions: 2023 EMA and FDA Guidance
Unraveling the implications and intricacies of recent regulatory guidance: from screenshot requirements to patient-focused drug development and beyond
Benefits of Oncology Image Collection Reconciliation
Proactive reconciliation of oncology imaging data is crucial for successfully expediting drug development
Advancing Electronic Clinical Outcome Assessments
Through recent EU, EMA, and FDA draft regulations
The Role of Patient Choice and Control
How BYOD creates patient-centric success in clinical trials
The Importance of Measuring Cognition in Oncology Trials
Enhance insights and patient outcomes with cognitive measurement strategies in cancer research
Maximizing Opportunities: Leveraging EMA Clinical Trials Regulation for Successful eCOA Studies in the EU
Navigating compliance, streamlining processes, and enhancing research outcomes
Improving accessibility in clinical trials
The impact of zoom functionality
Takeaways from the ACTRIMS Forum 2023
Strategies for Improving Inclusivity and Patient-Centricity in MS Clinical Trials
A pathway for replacing costly TQT studies
Bolstered by the recently approved S7B/E14 Q&A document, early-stage concentration-QTc analysis is emerging as a standard for assessing cardiac safety.
Prepared for Anything
With 50 years of experience, Clario relies on its evolution and resiliency to continue to help customers and patients
From clinical care to clinical trials
The importance of proper clinic BP assessment methods
Wet biomarkers commonly used in clinical trials
Empowering sites and sponsors to choose the correct aggregate of biomarkers for utmost accuracy
Total metabolic tumor volume — A valuable new method of assessment of global response to therapy
This measurement brings useful, independent, and correlative information to the clinical drug evaluation process
Future strategies in software quality engineering
Embedding quality into everyday practices makes organizations more flexible against industry changes
Health equity and ease of trial access
A fully stocked pharmacy can still mean empty shelves for many
Immunizations: Protecting the world from the ravages of disease
Clario celebrates National Immunization Awareness Month and our role in developing over 100 vaccines
New opinions and trends in oncology PROs
Learnings from the 2022 FDA COA in cancer trials workshop
Pride month celebrates our commitment to transforming lives
We celebrate our ongoing commitment to diversity and our ability to transform lives
Is there a future for NAFLD/NASH trials without biopsies?
How noninvasive imaging biomarkers can replace liver biopsies
Clario finds patients are as compliant at home as on-site
Patient-reported at-home PROs are a viable method for oncology clinical trials
FDA draft guidance on blood pressure monitoring in clinical trials
Addressing questions from members of the clinical, scientific, and regulatory communities
Creating hope, improving lives
Expressing gratitude for those who contribute to clinical research every day
eDiaries: How often is too often?
Best practices for receiving high compliance rates
World Earth Day: Sharing our sustainability initiatives and joining the UN Global Compact
Key initiatives in Clario’s sustainability strategy
Three ways to increase patient diversity in clinical trials
Safe and effective treatments for all are only possible if there is patient diversity in the clinical trials of those treatments
Oscillometry: An underutilized yet conclusive tool
Oscillometry is highly sensitive to picking up changes in lung
How to ensure lung safety is an important part of your trial protocol
To avoid risks, sponsors should consider lung function at the beginning of all trial planning
Correcting course when eCOA endpoint collection runs into trouble
How to navigate the expense, logistical hassles, and re-training involved in replacing critical technology or services during a study
How to improve respiratory data quality in non-respiratory clinical trials
Bettering the lives of patients through better respiratory data endpoints
Ensuring data quality in home spirometry
Best practices and key considerations with remote spirometry testing
What is important to patients in oncology clinical studies?
Considering patient burden when incorporating patient-reported outcomes in oncology
Is ePRO more than just a questionnaire?
ePROs have the potential to provide patients with greater flexibility and input in their participation in clinical trials
eCOA vs. paper
Which should I use for my upcoming trial?
What is eCOA?
Understanding its power and significance in clinical trials
Suicide risk assessment in clinical trial drug development: part 1
Assessing the positive and negative effects of medications on suicide risk to protect study participants
Suicide risk assessment in clinical trial drug development: part 2
In part 2, discover how new technology can help accurately evaluate suicidal ideation and behavior (SIB) in clinical trials
FDA guidance – patient-centered oncology research
Another Step Forward: FDA’s Core Patient-Reported Outcomes in Cancer Clinical Trials Draft Guidance for Industry